Drescher, C., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Behl, D., Ahn, E. R., … Schilsky, R. L. (2023). Nivolumab plus ipilimumab (N plus I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Drescher, Charles, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Deepti Behl, Eugene R. Ahn, Tareq Al Baghdadi, et al. “Nivolumab plus ipilimumab (N plus I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Drescher C, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Ahn ER, et al. Nivolumab plus ipilimumab (N plus I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Drescher, Charles, et al. “Nivolumab plus ipilimumab (N plus I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Drescher C, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Ahn ER, Al Baghdadi T, Naumann RW, Bell MC, Leath CA, Cannon TL, Alese OB, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Nivolumab plus ipilimumab (N plus I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JOURNAL OF CLINICAL ONCOLOGY. 2023.